Osiris Therapeutics leveled trade theft and breach-of-contract charges worth nearly $7 million against a regenerative medicine rival, stemming from the Stability Biologics acquisition by MiMedx (NSDQ:MDXG). Columbia, Md.-based Osiris said it inked a distribution deal back in 2013 to have Stability sell a pair of its products through the end of 2015. But after MiMedx paid $10 million for […]
MiMedx divests Stable Biologics subsidiary in transition to focus on biopharma
MiMedx (NSDQ:MDXG) said today it inked a definitive agreement with the former shareholders of Stability Inc. to divest itself of Stability Biologics, which it acquired last January. The Marietta, Ga.-based company said the divestiture is part of its plan to transition back into a biopharmaceutical-focused company. “The transaction is expected to be completed in the 3rd […]
MiMedx picks up regenerative focused Stability Biologics
MiMedx (NSDQ:MDXG) said it completed its acquisition of human tissue product provider Stability Biologics, paying $10 million at closing and saying it expected the buy to be accretive to its full year 2016 adjusted EPS. Nashville, Tenn.-based Stability Biologics produces tissue products at its national processing center in San Antonio, Texas, for use in surgical, spinal […]
